Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Gomella on Novel Biomarker Research in Prostate Cancer

December 20th 2021

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

FDA Approves TLX591-CDx for Prostate Cancer Imaging

December 20th 2021

The FDA has approved the imaging product TLX591-CDx as a radioactive diagnostic agent for PET of prostate-specific membrane antigen positive lesions in patients with prostate cancer who have suspected metastasis who are candidates for initial definitive therapy, and in those with suspected recurrence based on elevated serum prostate-specific antigen level.

Dr. Zurita-Saavedra on Leveraging Antiandrogen Agents in Metastatic HSPC

December 20th 2021

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer

December 17th 2021

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Dr. Siddiqui on Selecting Between Antiandrogen Agents in Nonmetastatic CRPC

December 14th 2021

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Shore on the Rationale for the Phase 2 ENACT Trial in Prostate Cancer

December 8th 2021

Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer.

FDA Grants 510K Clearance to Exablate System for Prostate Cancer

December 6th 2021

The FDA has awarded 510K clearance to the Exablate Prostate system for the treatment of prostate cancer.

Darolutamide Plus Docetaxel/ADT Significantly Improves OS in Metastatic Hormone-Sensitive Prostate Cancer

December 3rd 2021

The addition of darolutamide to docetaxel and androgen deprivation therapy resulted in a significant improvement in overall survival compared with docetaxel/ADT alone in patients with metastatic hormone-sensitive prostate cancer, meeting the primary end point of the phase 3 ARASENS trial.

Abiraterone/Docetaxel Combo Associated With Improved QOL Vs Docetaxel in mHSPC

November 30th 2021

Patients with locally advanced or metastatic hormone-sensitive prostate cancer who received docetaxel and abiraterone acetate plus prednisone or prednisolone and standard of care androgen deprivation therapy had superior patient-reported quality of life compared with patients who received docetaxel plus ADT, although the improvement narrowly missed the predefined value for clinical significance.

New ASTRO President Calls Attention to In-Person Meetings, Remaining Challenges, and Ongoing Research in Radiation Oncology

November 24th 2021

Jeff M. Michalski, MD, MBA, FASTRO, shares his presidential goals for ASTRO, the success of the hybrid 2021 ASTRO Annual Meeting, and remaining questions in radiation oncology that research efforts are poised to address.

Dr. Siddiqui on the Potential for Novel Imaging Techniques in Nonmetastatic CRPC

November 8th 2021

Bilal A. Siddiqui, MD, discusses the potential for novel imaging in patients with nonmetastatic castration-resistant prostate cancer.

Addition of ADT to Radiation, and Prolonged ADT, Provide Clinical Benefit in Localized Prostate Cancer

November 8th 2021

The use of androgen deprivation therapy and prolongation of adjuvant ADT to at least 18 months in conjunction with definitive radiotherapy provides clinically meaningful benefit for patients with localized prostate cancer, irrespective of radiation dose.

PSA Screening for Aggressive Prostate Cancer Supported in Men With Lynch Syndrome–Associated Pathogenic Variants

November 1st 2021

Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen screening from age 40 to identify men with clinically significant prostate cancer.

A New Era of Precision Medicine Takes Shape in Prostate Cancer

October 26th 2021

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

Dr. Subudhi on the Integration of Antiandrogen Agents in mHSPC

October 21st 2021

Sumit K. Subudhi, MD, PhD, discusses the integration of antiandrogen agents in metastatic hormone-sensitive prostate cancer.

New Class of Radiopharmaceutical Therapy Makes Headway in Prostate Cancer

October 21st 2021

Investigators have made great strides in the development of radiopharmaceuticals for prostate cancer diagnostics, culminating in recent FDA approvals for the first prostate-specific membrane antigen–targeted radioligands, gallium 68–PSMA-11 and piflufolastat F 18, for the detection of disease recurrence and metastatic lesions.

Dr. Zurita-Saavedra on Moving Therapies From mCRPC to mHSPC

October 19th 2021

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Subudhi on Future Directions With Immunotherapy in Prostate Cancer

October 18th 2021

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

ARCHES Final OS Analysis in mHSPC

October 15th 2021

Andrew J. Armstrong, MD, discusses final overall survival data from the phase 3 randomized, double-blind, placebo-controlled ARCHES study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer presented at the European Society for Medical Oncology 2021 Congress.

Dr. Siddiqui on the Current State of Treatment in Nonmetastatic CRPC

October 14th 2021

Bilal A. Siddiqui, MD, discusses the current state of treatment in nonmetastatic castration-resistant prostate cancer.